Molecular Partners Ag (MOLN) Total Non-Current Liabilities (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Total Non-Current Liabilities of $13289.8 for Q1 2026, up 203.34% year-over-year from $4381.2 in Q1 2025, and down 1.15% quarter-over-quarter from $13445.1 in Q4 2025.
Molecular Partners Ag (MOLN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Total Non-Current Liabilities for 7 consecutive years, with $13289.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 203.34% year-over-year to $13289.8; the TTM figure through Mar 2026 stood at $13289.8 (up 203.34% YoY), while the FY2025 annual figure was $13445.1, down 99.81% from the prior year.
- Total Non-Current Liabilities slipped to $13289.8 in Q1 2026 per MOLN's latest filing, from $13445.1 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.5 million in Q2 2022 and bottomed at $4381.2 in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $3.0 million across 5 years, with a median of $13289.8 in 2026.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities slumped 99.86% — and 2026, when it jumped 203.34%.
- Molecular Partners Ag's Total Non-Current Liabilities stood at $10.2 million in 2022, then decreased by 17.15% to $8.5 million in 2023, then retreated by 17.64% to $7.0 million in 2024, then tumbled by 99.81% to $13445.1 in 2025, then fell by 1.15% to $13289.8 in 2026.
- Business Quant data shows MOLN's Total Non-Current Liabilities at $13289.8 in Q1 2026, $13445.1 in Q4 2025, and $6099.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 13,289.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,289.79 |
| Dec 31, 2025 | 13,445.07 |
| Sep 30, 2025 | 6,099.28 |
| Jun 30, 2025 | 5,668.63 |
| Mar 31, 2025 | 4,381.15 |
| Dec 31, 2024 | 6.97 Mn |
| Sep 30, 2024 | 5,768.73 |
| Jun 30, 2024 | 4.08 Mn |
| Mar 31, 2024 | 5,478.65 |
| Dec 31, 2023 | 8.46 Mn |
| Sep 30, 2023 | 8,343.96 |
| Jun 30, 2023 | 9.84 Mn |
| Mar 31, 2023 | 7,560.57 |
| Dec 31, 2022 | 10.22 Mn |
| Sep 30, 2022 | 11,062.82 |
| Jun 30, 2022 | 10.49 Mn |
| Mar 31, 2022 | 18,313.54 |
| Dec 31, 2021 | 20.08 Mn |
| Sep 30, 2021 | 13,346.19 |
| Dec 31, 2020 | 25.06 Mn |